Carmustine polifeprosan 20 wafer

Drug Profile

Carmustine polifeprosan 20 wafer

Alternative Names: BCNU; BIODEL carmustine; Carmustine BIODEL; Gliadel; Gliadel® Wafer; NPC-08; NSC-409962; WR-139021

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Massachusetts Institute of Technology
  • Developer Arbor Pharmaceuticals; Eisai Co Ltd; Nobelpharma; Orphan Australia
  • Class Antineoplastics; Nitrosourea compounds; Small molecules
  • Mechanism of Action Alkylating agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Glioma

Most Recent Events

  • 02 Sep 2015 The Japanese MHLW lifts the all-case surveillance condition required for the approval of Gliadel® for the treatment of Glioma
  • 24 Apr 2015 Launched for Glioma in Mexico (Intracerebral)
  • 25 Mar 2015 Ranbaxy Laboratories has been acquired by Sun Pharmaceutical Industries
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top